Compare EH & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | REPL |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.8M | 692.8M |
| IPO Year | 2019 | 2018 |
| Metric | EH | REPL |
|---|---|---|
| Price | $9.88 | $2.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $22.47 | $5.67 |
| AVG Volume (30 Days) | 505.1K | ★ 9.7M |
| Earning Date | 05-26-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.23 | N/A |
| Revenue Next Year | $73.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.06 | $1.50 |
| 52 Week High | $20.44 | $13.24 |
| Indicator | EH | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 34.76 |
| Support Level | $9.06 | $1.50 |
| Resistance Level | $11.94 | $6.17 |
| Average True Range (ATR) | 0.41 | 0.53 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 4.41 | 22.07 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.